We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

LGN:NASDAQLegence Corp. Analysis

Data as of 2026-06-14 - not real-time

$86.00

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Legence Corp. (LGN) is trading at $86, comfortably above its 20‑day ($84.56) and 50‑day ($81.45) SMAs and the 200‑day SMA ($53.68), indicating a bullish price bias. The RSI sits at 52, suggesting neutral momentum, while the MACD is in a bearish configuration (negative histogram, bearish signal). Volatility is elevated at 67% over the past 30 days and the stock’s beta of 2.5 signals strong sensitivity to market swings.
The company just reported a spectacular 105% YoY revenue jump to $1.04 B in Q1, lifted its full‑year 2026 revenue outlook to $4.1‑$4.3 B and boasts a record $5.38 B backlog, underscoring robust demand in data‑center and technology projects. However, margins remain thin (gross 19.8%, operating 3.2%) and the firm posted a modest loss (‑0.7% profit margin) with a trailing EPS of –$0.34, while carrying $1.18 B of debt (Debt/Equity ≈ 124%). The DCF‑derived fair value of $67.4 is well below the current price, pointing to an overvalued valuation despite the growth narrative.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price above key moving averages supports bullish bias
  • Bearish MACD and decreasing volume signal short‑term weakness
  • High volatility and beta increase downside risk

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Revenue surged 105% YoY and backlog grew >100%
  • Forward EPS turning positive and guidance raised
  • Secular demand for data‑center HVAC and MEP services

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Strong secular growth tailwinds in the engineering & construction sector
  • Elevated leverage and thin margins constrain profitability
  • Current price exceeds DCF fair value, limiting upside potential

Key Metrics & Analysis

Financial Health

Revenue Growth105.10%
Profit Margin-0.73%
P/E Ratio48.5
ROE-7.22%
ROA2.40%
Debt/Equity123.90
P/B Ratio14.0
Op. Cash Flow$347.5M
Free Cash Flow$331.3M
Industry P/E30.6

Technical Analysis

TrendBullish
RSI52.1
Support$77.55
Resistance$90.35
MA 20$84.56
MA 50$81.45
MA 200$53.68
MACDBearish
VolumeDecreasing
Fear & Greed Index89.86

Valuation

Fair Value$67.41
Target Price$105.24
Upside/Downside22.37%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta2.50
Volatility67.00%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.